. HF has been shown to negatively impact a patient's quality of life by affecting their physical, psychological, social, and economic status 3 . Despite currently available therapies for HF, both mortality and hospitalization remain high 4, 5 . Approximately 22,000 deaths per year occur due to HF, comparable to the annual number of deaths from breast, colorectal, prostate and pancreatic cancer combined 6, 7 . HF presents a challenge to the healthcare system as it is the most common cause of an inpatient hospitalization in patients aged 65 or older, and prior cost studies demonstrated a substantial cost per HF hospitalization 8, 9 .
Approximately 600,000 Canadians are diagnosed with HF, however existing Canadian HF prevalence estimates use hospital and, where available, primary care diagnosis from databases which are limited in coverage and availability 10 . As HF has a large impact on the Canadian healthcare system, it is important to have up-to-date prevalence estimates.
OBJECTIVES
The objective of this study is to identify treated Canadian HF patients through the development of a model using retail prescription patterns from a national database to validate and build upon Canadian literature prevalence estimates. 
DATA SOURCE

CONCLUSION
The model's Canadian HF prevalence estimates closely match values found in literature both in overall and age stratified prevalence. As of 2014, approximately 2.31% of Canadians aged ≥18 are treated for HF. Overall, this study provides a mechanism to calculate detailed prevalence estimates in Canada when applied to retail prescription data.
RESULTS
Patients and Variables
• 675 HF patients and 840 randomly sampled non-HF patients were included to develop the CART model ( Figure 1 ). • Age and standardized duration treated with a beta-blocker, ACE/ARB, high-ceiling diuretic, and vasodilator were strong predictors of HF, while physician referral and gender were not. Model Accuracy • The model had 80.0% accuracy, 81.1% PPV, and 79.5% NPV when applied against the test dataset.
• Comparatively, a separate study found that a case definition of two HF diagnoses within all primary or secondary records or one HF diagnosis within all hospital records in a year had a positive predictive value of 55.6% 10 .
• Of the patients incorrectly predicted as HF when the model was applied to all patients treated with a cardiovascular ATC-1 treatment in the entire EMR dataset, 25.3% had a pre-HF diagnosis (e.g. hypertensive heart disease; old myocardial infarction; mitral insufficiency or stenosis; or pulmonary embolism with infarction).
Prevalence
• The study estimated a 2014 national aged ≥18 HF prevalence of 2.31%, or 657,902 treated patients.
• When applied to patients aged ≥40, the study estimated 648,493 HF treated patients, which aligned well with national literature estimates of 590,416 and 626,199 patients, which are based on diagnosis codes 10, 12 . It should be noted that the literature sources did not indicate that the identified patients were treated for their HF or identify the number of patients with HF without a recorded diagnosis.
• We expected a higher prevalence estimate, as compared to literature sources, as the model would identify HF patients in and out of the hospital, while the literature relied mostly on hospital discharge records. • When the model's prevalence estimates were stratified by patient age group, the majority differed by <0.5% from literature prevalence estimates (Table 1) . HF Definition: ‡ 1 hospital discharge abstract with an HF diagnosis code in any field or at least 2 physician claims within a 1-year period † 1 or more hospitalizations with a HF diagnosis code
METHODS
Phase 1: Develop and test predictive model
• A Classification and Regression Tree (CART) model predicting HF prescription patterns was constructed using the IMS E360 EMR database. • As it has been shown that class imbalance between the two cohorts, HF and non-HF, may result in poorer model accuracy, the dataset was balanced by randomly selecting non-HF patients for study inclusion resulting in an approximate 1:1.25 ratio of HF to non-HF patients 11 .
• Age, gender, prescriptions, referrals, and physician specialty variables were used in developing the CART model. • To aid in preventing overfitting, a minimum of 25 patients per final node was required.
• After training, the CART model's HF predictive accuracy was validated using a naïve test dataset of approximately 15% of the HF patients to establish the model's accuracy, positive and negative predictive values (PPV and NPV).
• Clinical opinion was engaged to confirm the rules generated by the statistical model.
Inclusion criteria -Phase 1
• Aged ≥18.
• ≥1 Anatomical Therapeutic Classification (ATC)-1 cardiovascular prescription.
• ≥2 doctor visits between January 2006 -January 2015.
• ≥1 HF diagnosis (International Classification of Diseases -Ninth Revision 428) used to positively identify a heart failure patient.
Phase 2: Application of predictive model to national LRx dataset
• To identify national HF patients, the CART model was applied to the national LRx dataset.
• All patients with >6 months follow-up in the LRx dataset were used to identify the prevalence of treated HF patients by age group. • The CART model's estimated prevalence of HF was then validated against current Canadian HF literature sources.
Inclusion criteria -Phase 2
• >6 months follow-up. Final cohort available for modeling N = 1,515
